Dennis M. Lanfear - 13 Jun 2023 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
President & CEO, Director
Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Dennis M. Lanfear
Issuer symbol
CHRS
Transactions as of
13 Jun 2023
Net transactions value
$0
Form type
4
Filing time
15 Jun 2023, 16:42:44 UTC
Previous filing
24 Jan 2023
Next filing
24 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Award $0 +225,000 $0.000000 225,000 13 Jun 2023 Common Stock 225,000 $5.44 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 50% of the shares on each anniversary measured from June 13, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.